Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on orthopedic treatments, is advancing its lead product GelrinC(R) through a U.S. pivotal clinical trial while already marketing the product in Europe. Executive Chairman and CEO Dr. Ehud Geller provided updates on the company's progress during an appearance on The BioMedWire Podcast, according to a recent announcement.
GelrinC(R) is a cell-free, off-the-shelf hydrogel implant designed to treat cartilage injuries in the knee. The implant is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. It is based on Regentis' Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone.
During the podcast, Geller noted that GelrinC(R) is approved for marketing in Europe and is currently undergoing a U.S. pivotal clinical trial. Regentis is working to expand clinical sites and complete enrollment around year-end. He also highlighted a U.S. market estimated at approximately 470,000 currently untreated cases annually for cartilage knee repair where no off-the-shelf treatment is available.
The company is pursuing European commercialization through discussions with distribution systems and major orthopedic companies. This dual approach—advancing clinical development in the U.S. while building commercial partnerships in Europe—positions Regentis to potentially capture a significant share of the orthopedic cartilage repair market.
For patients suffering from knee cartilage injuries, the development of an off-the-shelf, cell-free treatment could offer a more accessible option compared to existing therapies that may require multiple surgeries or cell harvesting. The large number of untreated cases in the U.S. underscores the unmet need for effective, ready-to-use solutions.
For the medical industry, Regentis' progress signals growing interest in regenerative medicine approaches for orthopedic conditions. The company's platform technology could pave the way for additional products targeting other tissue repair applications. As enrollment in the U.S. pivotal trial progresses, the results will be closely watched by investors and clinicians alike.
To view the full press release, visit https://ibn.fm/4Tu64. The latest news and updates relating to RGNT are available in the company's newsroom at https://ibn.fm/RGNT.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, produces The BioMedWire Podcast. The platform is part of a network that provides press release enhancement, article syndication, and social media distribution to reach a wide audience. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
